Jakavi 15mg Tablet

About

Jakavi (Ruxolitinib) 15mg Tablet is an oral Janus kinase (JAK) inhibitor used for the treatment of specific myeloproliferative neoplasms. It functions by selectively inhibiting JAK1 and JAK2, key enzymes in the signaling pathways of various cytokines and growth factors involved in blood cell production and immune responses. In conditions such as myelofibrosis, uncontrolled JAK signaling leads to excessive cell proliferation, inflammation, and bone marrow fibrosis. By blocking these pathways, Ruxolitinib effectively reduces an enlarged spleen, alleviates debilitating constitutional symptoms like fatigue, night sweats, and itching, and significantly improves the quality of life for affected patients. It is also indicated for polycythemia vera in individuals who have shown resistance or intolerance to hydroxyurea. Regular monitoring of blood counts is essential throughout treatment due to the risk of myelosuppression.

Uses

• Myelofibrosis (primary, post-polycythemia vera, post-essential thrombocythemia)
• Polycythemia vera (in patients resistant or intolerant to hydroxyurea)
• Chronic graft-versus-host disease (cGVHD)
• Acute graft-versus-host disease (aGVHD)

Directions For Use

Take orally with or without food, as prescribed by your doctor. Do not crush, chew, or split the tablet.

Benefits

• Reduces splenomegaly in myelofibrosis patients.
• Effectively manages constitutional symptoms like pruritus and fatigue.
• Improves overall quality of life for patients with myelofibrosis.
• Provides a treatment option for polycythemia vera resistant to other therapies.
• Helps control symptoms of graft-versus-host disease.
• Convenient oral dosage form.

Side Effects

• Thrombocytopenia
• Anemia
• Neutropenia
• Bruising
• Dizziness
• Headache
• Diarrhea
• Weight gain
• Increased susceptibility to infections (e.g., herpes zoster)
• Elevated cholesterol
• Liver enzyme abnormalities
• Fatigue

Safety Measures

• Alcohol - Limit alcohol consumption as it may exacerbate potential liver enzyme elevations.
• Pregnancy - Contraindicated during pregnancy; use reliable contraception due to potential harm to the fetus.
• Breastfeeding - Avoid breastfeeding as the drug may be excreted in breast milk and pose a risk to the infant.
• Liver - Dose adjustments are necessary for patients with hepatic impairment; monitor liver function tests regularly.
• Kidney - Dose adjustments are required for patients with renal impairment; monitor kidney function closely.
• Lung - Exercise caution in patients with active lung infections; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.